Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2012

01-03-2012 | Thoracic Oncology

XPC mRNA Level May Predict Relapse in Never-smokers with Non-Small Cell Lung Cancers

Authors: Kun-Tu Yeh, MD, PhD, Yi-Hui Wu, PhD, Ming-Ching Lee, MD, MS, Lee Wang, PhD, Chien-Te Li, MD, PhD, Chih-Yi Chen, MD, Huei Lee, PhD

Published in: Annals of Surgical Oncology | Issue 3/2012

Login to get access

Abstract

Background

Disease recurrence and distant metastasis are the major causes of death in resected non-small cell lung cancer (NSCLC). The prognostic marker for never-smokers with this disease remains to be identified. To improve patient outcome, establishing an adjacent molecular marker to predict relapse of NSCLC in never-smokers is needed.

Methods

Three hundred two lung tumors from NSCLC patients and normal lung tissues from 68 noncancer subjects were enrolled to evaluate XPC (xeroderma pigmentosum group C) mRNA expression by quantitative real-time reverse transcriptase polymerase chain reaction. Receiver operating characteristic curve analysis was used to search for a feasible cutoff point of XPC mRNA levels for predicting recurrence-free survival. Of the 326 patients, 214 were confirmed as only receiving surgical resection. Kaplan–Meier and multivariate Cox regression analysis were used to assess the prognostic value of XPC mRNA level in lung tumors from patients who only received surgical resection.

Results

Receiver operating characteristic curve analysis indicated 30.28 as a cutoff point, and thus 150 and 64 tumors with low- and high-XPC mRNA expression were categorized in this study population. Low-XPC mRNA appeared with more frequency in never-smokers and in late-stage (stage II–III) disease than smokers and early-stage disease (stage I). Kaplan–Meier analysis indicated that patients with low-XPC mRNA had shorter recurrence-free survival than that found in never-smokers (P = 0.002), but not in smokers (P = 0.296). Cox regression analysis further revealed that low-XPC mRNA may independently predict relapse in lung cancer of never-smokers (hazard ratio 2.34, 95% confidence interval 1.21–4.51, P = 0.011).

Conclusions

Low-XPC mRNA may predict relapse in lung cancer patients who are never-smokers.
Appendix
Available only for authorised users
Literature
1.
Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009;15:5646–61.PubMedCrossRef
2.
Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009;15:5626–45.PubMedCrossRef
3.
Rudin CM, Avila-Tang E, Samet JM. Lung cancer in never smokers: a call to action. Clin Cancer Res. 2009;15:5622–5.PubMedCrossRef
4.
5.
Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7:778–90.PubMedCrossRef
6.
Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472–8.PubMedCrossRef
7.
Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–51.PubMedCrossRef
8.
Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking statuses are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol. 2010;5:1001–10.PubMed
9.
Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol. 2009;4:1083–93.PubMedCrossRef
10.
Kawaguchi T, Takada M, Kubo A, et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol. 2010;5:1011–7.PubMed
11.
Nakamura H, Haruki T, Adachi Y, et al. Smoking affects prognosis after lung cancer surgery. Surg Today. 2008;38:227–31.PubMedCrossRef
12.
Hanagiri T, Sugio K, Mizukami M, et al. Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:1127–32.PubMedCrossRef
13.
Yano T, Miura N, Takenaka T, et al. Never-smoking nonsmall cell lung cancer as a separate entity. Cancer. 2008;113:1012–8.PubMedCrossRef
14.
Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007;132:185–92.
15.
Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.PubMedCrossRef
16.
Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.PubMedCrossRef
17.
Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol. 2004;22:811–9.PubMedCrossRef
18.
Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002;62:3005–8.PubMed
19.
Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with adenocarcinoma. Nat Med. 2002;8:816–24.PubMed
20.
Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, c-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer. 2000;83:473–9.PubMedCrossRef
21.
Wu YH, Cheng YW, Chang Tsai JH, et al. Reduced XPC messenger RNA level may predict a poor outcome of patients with non-small cell lung cancer. Cancer. 2007;110:215–23.PubMedCrossRef
22.
Sugasawa K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat Res. 2010;685:29–37.PubMedCrossRef
23.
Camenisch U, Trautlein D, Clement FC, et al. Two-stage dynamic DNA quality check by xeoderma pigmentosum group C protein. EMBO J. 2009;28:2387–99.PubMedCrossRef
24.
D’Errico M, Parlanti E, Teson M, et al. New functions of XPC in the protection of human skin cells from oxidative damage. EMBO J. 2006;25:4305–15.PubMedCrossRef
25.
Cheo DL, Burns DK, Meira LB, et al. Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53−/− mice. Cancer Res. 1999;59:771–5.PubMed
26.
Hollander MC, Philburn RT, Patterson AD, et al. Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci USA. 2005;102:13200–5.PubMedCrossRef
27.
Wu YH, Chang Tsai JH, Cheng YW, et al. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene. 2007;26:4761–73.PubMedCrossRef
28.
Wu YH, Wu TC, Liao JW, Yeh KT, et al. p53 dysfunction by xeroderma pigmentosum group C defects enhances lung adenocarcinoma metastasis via increased MMP1 expression. Cancer Res. 2010;70:10422–32.PubMedCrossRef
29.
World Health Organization. Histological typing of lung tumors. Am J Clin Pathol. 1982;77:123–36.
30.
Moutain CF. A new international staging system for lung cancer. Chest. 1986;89:225s–33s.
31.
Behars OH, Henson DE, Myers HH. Manual for staging of cancer. 4th ed. Philadelphia, PA: American Joint Committee on Cancer; 1992. p. 115–22.
32.
Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small cell lung cancer: a retrospective study. Lancet Oncol. 2007;8:889–97.PubMedCrossRef
33.
Subramanian J, Simon R. What should physicians look for in evaluating prognostic gene-expression signatures? Nat Med. 2010;7:327–34.
34.
Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102:464–74.PubMedCrossRef
35.
Bepler G, Sharma S, Cantor A, et al. RRM1 and PETN as prognostic parameters for overall and disease-free survival in patients with non-small cell lung cancer. J Clin Oncol. 2004;22:1878–85.PubMedCrossRef
36.
Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127:978–88.PubMedCrossRef
37.
Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 2010. doi:10.​1007/​s12032-010-9553-9.
38.
Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small cell lung cancer. PLoS One. 2007;2:e1129.PubMedCrossRef
39.
Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003;22:2135–42.PubMedCrossRef
40.
Fan H, Huang A, Villegas C, Wright JA. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA. 1997;94:13181–6.PubMedCrossRef
41.
Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66:6497–502.PubMedCrossRef
42.
Yang J, Xu Z, Li J, et al. XPC epigenetic silence coupled with p53 alternation has a significant impact on bladder cancer outcome. J Urol. 2010;184:336–43.PubMedCrossRef
43.
Li M, Xiao T, Zhang Y, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumor tissues of lung cancer patients. Lung Cancer. 2010;69:341–7.PubMedCrossRef
Metadata
Title
XPC mRNA Level May Predict Relapse in Never-smokers with Non-Small Cell Lung Cancers
Authors
Kun-Tu Yeh, MD, PhD
Yi-Hui Wu, PhD
Ming-Ching Lee, MD, MS
Lee Wang, PhD
Chien-Te Li, MD, PhD
Chih-Yi Chen, MD
Huei Lee, PhD
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1992-9

Other articles of this Issue 3/2012

Annals of Surgical Oncology 3/2012 Go to the issue

Pancreatic Tumors

Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients

Pancreatic Tumors

Outcomes After Robot-Assisted Pancreaticoduodenectomy for Periampullary Lesions

Thoracic Oncology

Expression Analysis Elucidates the Roles of MAML1 and Twist1 in Esophageal Squamous Cell Carcinoma Aggressiveness and Metastasis

Gastrointestinal Oncology

Additive Lymph Node Dissection may be Necessary in Minute Submucosal Cancer of the Stomach after Endoscopic Resection

Hepatobiliary Tumors

Patterns of Recurrence After Ablation of Colorectal Cancer Liver Metastases

Gynecologic Oncology

Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer